Novel Nanoparticles for Photothermal and Photodynamic Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (1 December 2022) | Viewed by 4249
Special Issue Editors
Interests: drug delivery systems; lipid-based systems; liposomes; pharmacokinetic studies; biodistribution studies; murine tumor models; cancer; inflammation; melanoma; colon cancer; pancreatic cancer; preclinical studies
Special Issues, Collections and Topics in MDPI journals
Interests: development of new drug delivery systems; therapeutic polymers for drug delivery; methods of micro- and nanoencapsulation of drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Photothermal therapy has emerged as a highly promising strategy for the treatment of superficial and localized tumors. It is a minimally invasive technique that takes advantage of the increased sensitivity of cancer cells to heat, relying on the induction of thermal ablation of tumor cells through irradiation with light beams. In addition, it is also considered safe, enabling a faster recovery of the patient compared with other existing therapeutic approaches.
An overview of several nanoparticles for photothermal and photodynamic therapy will be herein presented, with a focus on different methods of preparation and in vitro and in vivo studies, including clinical studies using this nanotechnological approach for cancer management.
Dr. Maria Manuela Gaspar
Dr. Catarina Pinto Reis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photosensitizing agents
- photoimmunotherapy
- lipid-based systems
- gold nanoparticles
- polymeric nanoparticles
- photothermal therapy
- cancer
- in vitro and in vivo studies
- efficacy and safety assessment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
